Showing posts with label Articles. Show all posts
Showing posts with label Articles. Show all posts

Wednesday, 28 September 2016

Winpain




Winpain may be available in the countries listed below.


Ingredient matches for Winpain



Tramadol

Tramadol hydrochloride (a derivative of Tramadol) is reported as an ingredient of Winpain in the following countries:


  • Bangladesh

International Drug Name Search

Ritrocel




Ritrocel may be available in the countries listed below.


Ingredient matches for Ritrocel



Methylphenidate

Methylphenidate hydrochloride (a derivative of Methylphenidate) is reported as an ingredient of Ritrocel in the following countries:


  • Chile

International Drug Name Search

Antigrippine Ibuprofen




Antigrippine Ibuprofen may be available in the countries listed below.


Ingredient matches for Antigrippine Ibuprofen



Ibuprofen

Ibuprofen is reported as an ingredient of Antigrippine Ibuprofen in the following countries:


  • Netherlands

International Drug Name Search

Prometrium


Prometrium is a brand name of progesterone, approved by the FDA in the following formulation(s):


PROMETRIUM (progesterone - capsule; oral)



  • Manufacturer: ABBOTT LABS

    Approval date: May 14, 1998

    Strength(s): 100MG


  • Manufacturer: ABBOTT LABS

    Approval date: October 15, 1999

    Strength(s): 200MG [RLD]

Has a generic version of Prometrium been approved?


No. There is currently no therapeutically equivalent version of Prometrium available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Prometrium. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Prometrium.

See also...

  • Prometrium Consumer Information (Wolters Kluwer)
  • Prometrium Consumer Information (Cerner Multum)
  • Progesterone Consumer Information (Drugs.com)
  • Progesterone Consumer Information (Wolters Kluwer)
  • Progesterone Gel Consumer Information (Wolters Kluwer)
  • Progesterone Insert Consumer Information (Wolters Kluwer)
  • Progesterone Oil Consumer Information (Wolters Kluwer)
  • FIRST-Progesterone VGS 100 Consumer Information (Cerner Multum)
  • FIRST-Progesterone VGS 200 Consumer Information (Cerner Multum)
  • FIRST-Progesterone VGS 25 Consumer Information (Cerner Multum)
  • FIRST-Progesterone VGS 400 Consumer Information (Cerner Multum)
  • FIRST-Progesterone VGS 50 Consumer Information (Cerner Multum)
  • Progesterone Consumer Information (Cerner Multum)
  • Progesterone vaginal Consumer Information (Cerner Multum)
  • Progesterone AHFS DI Monographs (ASHP)

Ocuflox


Ocuflox is a brand name of ofloxacin ophthalmic, approved by the FDA in the following formulation(s):


OCUFLOX (ofloxacin - solution/drops; ophthalmic)



  • Manufacturer: ALLERGAN

    Approval date: July 30, 1993

    Strength(s): 0.3% [RLD][AT]

Has a generic version of Ocuflox been approved?


Yes. The following products are equivalent to Ocuflox:


ofloxacin solution/drops; ophthalmic



  • Manufacturer: AKORN

    Approval date: April 15, 2008

    Strength(s): 0.3% [AT]


  • Manufacturer: ALCON PHARMS LTD

    Approval date: May 14, 2004

    Strength(s): 0.3% [AT]


  • Manufacturer: BAUSCH AND LOMB

    Approval date: May 14, 2004

    Strength(s): 0.3% [AT]


  • Manufacturer: FDC LTD

    Approval date: February 25, 2009

    Strength(s): 0.3% [AT]


  • Manufacturer: FERA PHARMS

    Approval date: August 31, 2004

    Strength(s): 0.3% [AT]


  • Manufacturer: HI TECH PHARMA

    Approval date: May 14, 2004

    Strength(s): 0.3% [AT]


  • Manufacturer: NOVEX

    Approval date: May 14, 2004

    Strength(s): 0.3% [AT]


  • Manufacturer: SANDOZ

    Approval date: November 25, 2008

    Strength(s): 0.3% [AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ocuflox. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Ocuflox.

See also...

  • Ocuflox Drops Consumer Information (Wolters Kluwer)
  • Ocuflox Consumer Information (Cerner Multum)
  • Ocuflox Advanced Consumer Information (Micromedex)
  • Ofloxacin Drops Consumer Information (Wolters Kluwer)
  • Ofloxacin ophthalmic Consumer Information (Cerner Multum)
  • Ophtho-Flox Advanced Consumer Information (Micromedex)
  • Ofloxacin Ophthalmic Advanced Consumer Information (Micromedex)
  • Ofloxacin eent AHFS DI Monographs (ASHP)

Zerlor


Generic Name: acetaminophen, caffeine, and dihydrocodeine (a SEET a MIN oh fen, KAF een, dye HYE droe KOE deen)

Brand Names: Panlor SS, Trezix, Zerlor


What is Zerlor (acetaminophen, caffeine, and dihydrocodeine)?

Dihydrocodeine a narcotic pain reliever.


Acetaminophen is a less potent pain reliever that increases the effects of dihydrocodeine.


Caffeine is a central nervous system stimulant. It relaxes muscle contractions in blood vessels to improve blood flow.


The combination of acetaminophen, caffeine, and dihydrocodeine is used to relieve moderate to severe pain.


Acetaminophen, caffeine, and dihydrocodeine may also be used for purposes not listed in this medication guide.


What is the most important information I should know about Zerlor (acetaminophen, caffeine, and dihydrocodeine)?


Tell your doctor if you have ever had alcoholic liver disease (cirrhosis) or if you drink more than 3 alcoholic beverages per day. You may not be able to take medicine that contains acetaminophen. Do not take more of this medication than is recommended. An overdose of acetaminophen can damage your liver or cause death. Avoid drinking alcohol. It may increase your risk of liver damage while taking acetaminophen. Dihydrocodeine may be habit-forming and should be used only by the person it was prescribed for. Keep the medication in a secure place where others cannot get to it. This medication may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert.

Tell your doctor if the medicine seems to stop working as well in relieving your pain.


What should I discuss with my healthcare provider before taking Zerlor (acetaminophen, caffeine, and dihydrocodeine)?


Do not use this medication if you are allergic to acetaminophen (Tylenol) or dihydrocodeine, or if you have a stomach condition called paralytic ileus, or severe or uncontrolled asthma. Tell your doctor if you have ever had alcoholic liver disease (cirrhosis) or if you drink more than 3 alcoholic beverages per day. You may not be able to take medicine that contains acetaminophen. Dihydrocodeine may be habit forming and should be used only by the person it was prescribed for. Never share acetaminophen, caffeine, and dihydrocodeine with another person, especially someone with a history of drug abuse or addiction. Keep the medication in a place where others cannot get to it.

To make sure you can safely take this medicine, tell your doctor if you have any of these other conditions:



  • sleep apnea or other breathing disorders;




  • liver or kidney disease;




  • a history of head injury or brain tumor;




  • epilepsy or other seizure disorder;




  • low blood pressure;




  • a stomach or intestinal disorder;




  • underactive thyroid;




  • a pancreas disorder;




  • Addison's disease or other adrenal gland disorder;




  • enlarged prostate, urination problems;




  • curvature of the spine;




  • mental illness; or




  • a history of drug or alcohol addiction.




FDA pregnancy category C. It is not known whether this medication is harmful to an unborn baby, but it could cause breathing problems or addiction/withdrawal symptoms in a newborn. Tell your doctor if you are pregnant or plan to become pregnant while using acetaminophen, caffeine, and dihydrocodeine. Dihydrocodeine can pass into breast milk and may harm a nursing baby. The use of this medication by some nursing mothers may lead to life-threatening side effects in the baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I take Zerlor (acetaminophen, caffeine, and dihydrocodeine)?


Take exactly as prescribed. Never take acetaminophen, caffeine, and dihydrocodeine in larger amounts, or for longer than recommended by your doctor. Follow the directions on your prescription label. Tell your doctor if the medicine seems to stop working as well in relieving your pain.


Do not take more of this medication than is recommended. An overdose of acetaminophen can damage your liver or cause death. Do not stop using acetaminophen, caffeine, and dihydrocodeine suddenly after long-term use, or you could have unpleasant withdrawal symptoms. Ask your doctor how to avoid withdrawal symptoms when you stop using acetaminophen, caffeine, and dihydrocodeine. This medication can cause unusual results with certain medical tests. Tell any doctor who treats you that you are using acetaminophen, caffeine, and dihydrocodeine. If you need surgery, tell the surgeon ahead of time that you are using acetaminophen, caffeine, and dihydrocodeine. You may need to stop using the medicine for a short time. Store at room temperature away from moisture and heat.

Keep track of the amount of medicine used from each new bottle. Acetaminophen, caffeine, and dihydrocodeine is a drug of abuse and you should be aware if anyone is using your medicine improperly or without a prescription.


What happens if I miss a dose?


Since acetaminophen, caffeine, and dihydrocodeine is taken as needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222. An overdose of acetaminophen, caffeine, and dihydrocodeine can be fatal.

The first signs of an acetaminophen overdose include loss of appetite, nausea, vomiting, stomach pain, sweating, and confusion or weakness. Later symptoms may include pain in your upper stomach, dark urine, and yellowing of your skin or the whites of your eyes.


Overdose symptoms may also include extreme drowsiness or insomnia, restless feeling, tremors, fast heart rate, pinpoint pupils, fainting, weak pulse, seizure (convulsions), coma, blue lips, shallow breathing, or no breathing.


What should I avoid while taking Zerlor (acetaminophen, caffeine, and dihydrocodeine)?


Avoid drinking alcohol. It may increase your risk of liver damage while taking acetaminophen. This medication may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert. Ask a doctor or pharmacist before using any other cold, allergy, pain, or sleep medication. Acetaminophen (sometimes abbreviated as APAP) is contained in many combination medicines. Taking certain products together can cause you to get too much acetaminophen which can lead to a fatal overdose. Check the label to see if a medicine contains acetaminophen or APAP.

While you are taking this medication, avoid taking diet pills, caffeine pills, or other stimulants (such as ADHD medications) without your doctor's advice.


Zerlor (acetaminophen, caffeine, and dihydrocodeine) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat. Stop using acetaminophen, caffeine, and dihydrocodeine and call your doctor at once if you have a serious side effect such as:

  • shallow breathing, slow heartbeat;




  • fast or pounding heart rate, feeling light-headed, fainting;




  • confusion, hallucinations, unusual thoughts or behavior;




  • muscle twitching;




  • problems with urination;




  • easy bruising or bleeding; or




  • nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).



Less serious side effects include:



  • feeling dizzy or drowsy, shaky or agitated;




  • mild nausea, vomiting, upset stomach; constipation, diarrhea;




  • mood changes, sleep problems (insomnia);




  • sweating, urinating more than usual;




  • ringing in your ears, blurred vision; or




  • dry mouth.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Zerlor (acetaminophen, caffeine, and dihydrocodeine)?


Before using this medication, tell your doctor if you regularly use other medicines that make you sleepy (such as cold or allergy medicine, sedatives, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression, or anxiety). They can add to sleepiness caused by dihydrocodeine.

Tell your doctor about all other medicines you use, especially:



  • ciprofloxacin (Cipro);




  • atropine (Donnatal, and others), benztropine (Cogentin), dimenhydrinate (Dramamine), glycopyrrolate (Robinul), isoniazid, mepenzolate (Cantil), methscopolamine (Pamine), or scopolamine (Transderm-Scop);




  • bladder or urinary medications such as oxybutynin (Ditropan, Oxytrol), tolterodine (Detrol), or solifenacin (Vesicare);




  • a blood thinner such as warfarin (Coumadin, Jantoven);




  • a bronchodilator such as ipratropium (Atrovent) or tiotropium (Spiriva);




  • irritable bowel medications such as dicyclomine (Bentyl), hyoscyamine (Anaspaz, Levsin, and others), or propantheline (Pro-Banthine);




  • seizure medicine such as carbamazepine (Carbatrol, Equetro, Tegretol) or phenytoin (Dilantin); or




  • an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate).



This list is not complete and other drugs may interact with acetaminophen, caffeine, and dihydrocodeine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Zerlor resources


  • Zerlor Side Effects (in more detail)
  • Zerlor Use in Pregnancy & Breastfeeding
  • Zerlor Drug Interactions
  • Zerlor Support Group
  • 0 Reviews for Zerlor - Add your own review/rating


  • Panlor DC MedFacts Consumer Leaflet (Wolters Kluwer)

  • Trezix Prescribing Information (FDA)



Compare Zerlor with other medications


  • Pain


Where can I get more information?


  • Your pharmacist can provide more information about acetaminophen, caffeine, and dihydrocodeine.

See also: Zerlor side effects (in more detail)


Iopimax




Iopimax may be available in the countries listed below.


Ingredient matches for Iopimax



Apraclonidine

Apraclonidine hydrochloride (a derivative of Apraclonidine) is reported as an ingredient of Iopimax in the following countries:


  • Spain

International Drug Name Search

Precedex


Precedex is a brand name of dexmedetomidine, approved by the FDA in the following formulation(s):


PRECEDEX (dexmedetomidine hydrochloride - injectable; injection)



  • Manufacturer: HOSPIRA

    Approval date: December 17, 1999

    Strength(s): EQ 100MCG BASE/ML (EQ100MCG BASE/ML) [RLD]

Has a generic version of Precedex been approved?


No. There is currently no therapeutically equivalent version of Precedex available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Precedex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Optical isomer of an imidazole derivative medetomidine as an alpha-2-receptor agonist
    Patent 4,910,214
    Issued: March 20, 1990
    Inventor(s): Karjalainen; Arto J. & Virtanen; Raimo E. & Savolainen; Eino J.
    Assignee(s): Farmos Yhtyma Oy
    The separated d and l enantiomers of medetomidine and their salts are selective and potent .alpha..sub.2 -receptor agonists.
    Patent expiration dates:

    • July 15, 2013
      ✓ 
      Patent use: USE FOR SEDATION
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • 4-substituted imidazole derivatives useful in perioperative care
    Patent 5,344,840
    Issued: September 6, 1994
    Inventor(s): Maze; Mervyn & Scheinin; Mika
    Assignee(s): Orion-Yhtyma OY
    4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, known as medetomidine, and in particular its d-enantiomer and salts thereof are useful in perioperative care, in particular in reducing the amount of anaesthetic it is necessary to administer.
    Patent expiration dates:

    • September 6, 2011
      ✓ 
      Patent use: SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES




  • Use of dexmedetomidine for ICU sedation
    Patent 6,716,867
    Issued: April 6, 2004
    Inventor(s): Riku; Aantaa & Romeo; Bachand & Esa; Heinonen
    Assignee(s): Orion Corporation
    The present invention relates to a method of sedating a patient while in the intensive care unit comprising administering dexmedetomidine of a pharmaceutically acceptable salt thereof to the patient, wherein the patient remains arousable and orientated.
    Patent expiration dates:

    • March 31, 2019
      ✓ 
      Patent use: INTENSIVE CARE UNIT SEDATION



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • October 17, 2011 - SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCUDURES

See also...

  • Precedex AHFS DI Monographs (ASHP)
  • Dexmedetomidine Hydrochloride AHFS DI Monographs (ASHP)

Plendil


Plendil is a brand name of felodipine, approved by the FDA in the following formulation(s):


PLENDIL (felodipine - tablet, extended release; oral)



  • Manufacturer: ASTRAZENECA

    Approval date: July 25, 1991

    Strength(s): 10MG [AB], 5MG [AB]


  • Manufacturer: ASTRAZENECA

    Approval date: September 22, 1994

    Strength(s): 2.5MG [AB]

Has a generic version of Plendil been approved?


Yes. The following products are equivalent to Plendil:


felodipine tablet, extended release; oral



  • Manufacturer: ENDO PHARMS

    Approval date: October 28, 2011

    Strength(s): 10MG [AB], 2.5MG [AB], 5MG [AB]


  • Manufacturer: GLENMARK GENERICS

    Approval date: December 17, 2010

    Strength(s): 10MG [AB], 2.5MG [AB], 5MG [AB]


  • Manufacturer: MUTUAL PHARM

    Approval date: November 2, 2004

    Strength(s): 10MG [AB], 2.5MG [AB], 5MG [AB]


  • Manufacturer: MYLAN

    Approval date: April 17, 2008

    Strength(s): 2.5MG [AB], 5MG [AB]


  • Manufacturer: TORRENT PHARMS LTD

    Approval date: November 28, 2011

    Strength(s): 10MG [AB], 2.5MG [AB], 5MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Plendil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Plendil.

See also...

  • Plendil Consumer Information (Drugs.com)
  • Plendil Consumer Information (Wolters Kluwer)
  • Plendil Consumer Information (Cerner Multum)
  • Plendil Advanced Consumer Information (Micromedex)
  • Plendil AHFS DI Monographs (ASHP)
  • Felodipine Consumer Information (Wolters Kluwer)
  • Felodipine Consumer Information (Cerner Multum)
  • Felodipine Advanced Consumer Information (Micromedex)
  • Felodipine AHFS DI Monographs (ASHP)

Prevpac


Prevpac is a brand name of amoxicillin/clarithromycin/lansoprazole, approved by the FDA in the following formulation(s):


PREVPAC (amoxicillin; clarithromycin; lansoprazole - capsule, tablet, capsule, delayed rel pellets; oral)



  • Manufacturer: TAKEDA PHARMS NA

    Approval date: December 2, 1997

    Strength(s): 500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG [RLD]

Has a generic version of Prevpac been approved?


No. There is currently no therapeutically equivalent version of Prevpac available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Prevpac. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Prevpac.

See also...

  • Prevpac Therapy Pack Consumer Information (Wolters Kluwer)
  • Prevpac Consumer Information (Cerner Multum)
  • Amoxicillin/Clarithromycin/Lansoprazole Therapy Pack Consumer Information (Wolters Kluwer)
  • Amoxicillin, clarithromycin, and lansoprazole Consumer Information (Cerner Multum)

Midamor


Midamor is a brand name of amiloride, approved by the FDA in the following formulation(s):


MIDAMOR (amiloride hydrochloride - tablet; oral)



  • Manufacturer: PADDOCK LLC

    Approved Prior to Jan 1, 1982

    Strength(s): 5MG [AB]

Has a generic version of Midamor been approved?


Yes. The following products are equivalent to Midamor:


amiloride hydrochloride tablet; oral



  • Manufacturer: SIGMAPHARM LABS LLC

    Approval date: January 30, 2009

    Strength(s): 5MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Midamor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Midamor.

See also...

  • Midamor Consumer Information (Wolters Kluwer)
  • Midamor Consumer Information (Cerner Multum)
  • Midamor Advanced Consumer Information (Micromedex)
  • Midamor AHFS DI Monographs (ASHP)
  • Amiloride Consumer Information (Wolters Kluwer)
  • Amiloride Consumer Information (Cerner Multum)
  • Amiloride Advanced Consumer Information (Micromedex)
  • Amiloride Hydrochloride AHFS DI Monographs (ASHP)

Prinzide


Prinzide is a brand name of hydrochlorothiazide/lisinopril, approved by the FDA in the following formulation(s):


PRINZIDE (hydrochlorothiazide; lisinopril - tablet; oral)



  • Manufacturer: MERCK

    Approval date: February 16, 1989

    Strength(s): 12.5MG;20MG [AB]


  • Manufacturer: MERCK

    Approval date: November 18, 1993

    Strength(s): 12.5MG;10MG [AB]

Has a generic version of Prinzide been approved?


Yes. The following products are equivalent to Prinzide:


LISINOPRIL AND HYDROCHLOROTHIAZIDE (hydrochlorothiazide; lisinopril tablet; oral)



  • Manufacturer: APOTEX INC

    Approval date: October 5, 2004

    Strength(s): 12.5MG;10MG [AB], 12.5MG;20MG [AB]


  • Manufacturer: AUROBINDO

    Approval date: March 14, 2006

    Strength(s): 12.5MG;10MG [AB], 12.5MG;20MG [AB]


  • Manufacturer: IVAX SUB TEVA PHARMS

    Approval date: July 1, 2002

    Strength(s): 12.5MG;10MG [AB], 12.5MG;20MG [AB]


  • Manufacturer: LUPIN

    Approval date: September 27, 2006

    Strength(s): 12.5MG;10MG [AB], 12.5MG;20MG [AB]


  • Manufacturer: MYLAN

    Approval date: July 1, 2002

    Strength(s): 12.5MG;10MG [AB], 12.5MG;20MG [AB]


  • Manufacturer: PRINSTON INC

    Approval date: July 1, 2002

    Strength(s): 12.5MG;10MG [AB], 12.5MG;20MG [AB]


  • Manufacturer: RANBAXY

    Approval date: July 1, 2002

    Strength(s): 12.5MG;10MG [AB], 12.5MG;20MG [AB]


  • Manufacturer: SANDOZ

    Approval date: July 1, 2002

    Strength(s): 12.5MG;10MG [AB], 12.5MG;20MG [AB]


  • Manufacturer: WATSON LABS

    Approval date: July 1, 2002

    Strength(s): 12.5MG;10MG [AB], 12.5MG;20MG [AB]


  • Manufacturer: WEST WARD

    Approval date: July 8, 2002

    Strength(s): 12.5MG;10MG [AB], 12.5MG;20MG [AB]

ZESTORETIC (hydrochlorothiazide; lisinopril tablet; oral)



  • Manufacturer: ASTRAZENECA

    Approval date: November 18, 1993

    Strength(s): 12.5MG;10MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Prinzide. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Prinzide.

See also...

  • Prinzide Consumer Information (Wolters Kluwer)
  • Prinzide Consumer Information (Cerner Multum)
  • Prinzide Advanced Consumer Information (Micromedex)
  • Lisinopril/Hydrochlorothiazide Consumer Information (Wolters Kluwer)
  • Hydrochlorothiazide and lisinopril Consumer Information (Cerner Multum)
  • Lisinopril and hydrochlorothiazide Advanced Consumer Information (Micromedex)

Multihance


Multihance is a brand name of gadobenate dimeglumine, approved by the FDA in the following formulation(s):


MULTIHANCE (gadobenate dimeglumine - injectable; intravenous)



  • Manufacturer: BRACCO

    Approval date: November 23, 2004

    Strength(s): 10.58GM/20ML (529MG/ML) [RLD], 2.645GM/5ML (529MG/ML) [RLD], 5.29GM/10ML (529MG/ML) [RLD], 7.935GM/15ML (529MG/ML) [RLD]

Has a generic version of Multihance been approved?


No. There is currently no therapeutically equivalent version of Multihance available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Multihance. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Paramagnetic chelates useful for NMR imaging
    Patent 4,916,246
    Issued: April 10, 1990
    Inventor(s): Felder; Ernst & Uggeri; Fulvio & Fumagalli; Luciano & Vittadini; Giorgio
    Assignee(s): Bracco Chimica S.p.A.
    Compounds suitable for NMR imaging having the formula: ##STR1## wherein a is 2 or 3; b is an integer from 0 to 4; Me.sup.(a+) is Fe.sup.(2+), Fe.sup.(3+), Gd.sup.(3+), or Mn.sup.(2+) ; E.sup.(b+) is an ion of an alkali metal, alkaline earth metal, alkyl ammonium, alkanol ammonium, polyhydroxyalkyl ammonium, or basic protonated amino acid, said ions representing a total charge of b; m is an integer from 1 to 5; R is H, alkyl with from 1 to 8 carbon atoms, alkyl with from 1 to 8 carbon atoms wherein from 1 to 5 carbons are substituted with OH; aralkyl with 1 to 4 aliphatic carbon atoms; phenyl or phenyl substituted by halogen, hydroxyl, carboxyl, carboxamide, ester, SO.sub.3 H, sulfonamide, lower alkyl, lower hydroxy alkyl, amino, acylamino; (poly)oxa-alkyl with 1 to 50 oxygen atoms and from 3 to 150 carbon atoms, wherein 1 to 5 hydrogen atoms may be substituted by OH; R.sub.1 is the same as R.sub.2 or is --CH.sub.2 COOZ, --CH(CH.sub.3)COOZ, CH.sub.2 CH.sub.2 --N(CH.sub.2 COOZ).sub.2, a hydroxy arylalkyl, hydroxy pyridylalkyl, hydroxy aryl(carboxy)alkyl or hydroxy pyridyl-(carboxy)alkyl radical, where the aryl or pyridyl radical may be substituted by hydroxyl, hydroxy alkyl, alkyl, halogen, carboxyl or SO.sub.3 H; R.sub.2 is --CH.sub.2 COOZ, --CH(CH.sub.3)COOZ, ##STR2## wherein R.sub.3 is --CH.sub.2 COOZ, --CH(CH.sub.3)COOZ or a monovalent radical having the structure ##STR3## X is a direct chemical bond, --O--, --S--, --NH--, ##STR4## n is the integer 2 or 3, with the proviso that when X represents a direct bond, n is 1, 2 or 3; Z is hydrogen or a unit of negative charge, and --(CH.sub.2).sub.m -- may also be --CH.sub.2 --C(CH.sub.3).sub.2 --.
    Patent expiration dates:

    • April 10, 2012
      ✓ 
      Drug substance



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • March 17, 2013 - NEW PATIENT POPULATION

See also...

  • Multihance Consumer Information (Cerner Multum)
  • Multihance Advanced Consumer Information (Micromedex)
  • Gadobenate dimeglumine Consumer Information (Cerner Multum)
  • Gadobenate Intravenous Advanced Consumer Information (Micromedex)

Tears Again Mc


Generic Name: hypromellose (Ophthalmic route)

hye-PROE-me-lose

Commonly used brand name(s)

In the U.S.


  • Genteal

  • Genteal Mild

  • Gonak

  • Goniosoft

  • Goniovisc

  • Isopto Tears

  • Nature's Tears

  • Tearisol

  • Tears Again Mc

Available Dosage Forms:


  • Solution

  • Gel/Jelly

Therapeutic Class: Surgical Aid, Ocular


Uses For Tears Again Mc


Hydroxypropyl methylcellulose belongs to the group of medicines known as artificial tears. It is used to relieve dryness and irritation caused by reduced tear flow. It helps prevent damage to the eye in certain eye diseases. Hydroxypropyl methylcellulose may also be used to moisten hard contact lenses and artificial eyes. In addition, it may be used in certain eye examinations.


Some of these preparations are available only with your doctor's prescription.


Before Using Tears Again Mc


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Although there is no specific information comparing use of hydroxypropyl methylcellulose in children with use in other age groups, this medicine is not expected to cause different side effects or problems in children than it does in adults.


Geriatric


Many medicine have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults. Although there is no specific information comparing use of hydroxypropyl methylcellulose in the elderly with use in other age groups, this medicine is not expected to cause different side effects or problems in older people than it does in younger adults.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersCAnimal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding


There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.


Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Proper Use of hypromellose

This section provides information on the proper use of a number of products that contain hypromellose. It may not be specific to Tears Again Mc. Please read with care.


To use:


  • First, wash your hands. Then tilt the head back and pull the lower eyelid away from the eye to form a pouch. Drop the medicine into the pouch and gently close the eyes. Do not blink. Keep the eyes closed for 1 or 2 minutes to allow the medicine to be absorbed.

  • To keep the medicine as germ-free as possible, do not touch the applicator tip to any surface (including the eye). Also, keep the container tightly closed.

For patients wearing hard contact lenses:


  • Take care not to float the lens from your eye when applying this medicine. If you have any questions about this, check with your health care professional.

Dosing


The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For dry eyes:
    • For ophthalmic solution (eye drops) dosage form:
      • Adults and children—Use 1 drop three or four times a day.



Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Precautions While Using Tears Again Mc


If you experience eye pain, changes in vision, continued redness or irritation of the eye, or if your symptoms continue for more than 3 days or become worse, check with your doctor.


Tears Again Mc Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor as soon as possible if any of the following side effects occur:


  • Eye irritation not present before use of this medicine

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


Less common - more common with 1% solution
  • Blurred vision

  • matting or stickiness of eyelashes

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

Pexeva


Pexeva is a brand name of paroxetine, approved by the FDA in the following formulation(s):


PEXEVA (paroxetine mesylate - tablet; oral)



  • Manufacturer: NOVEN THERAP

    Approval date: July 3, 2003

    Strength(s): EQ 10MG BASE, EQ 20MG BASE, EQ 30MG BASE, EQ 40MG BASE [RLD]

Has a generic version of Pexeva been approved?


No. There is currently no therapeutically equivalent version of Pexeva available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Pexeva. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • 4-Phenylpiperidine compounds for treating depression
    Patent 5,874,447
    Issued: February 23, 1999
    Inventor(s): Benneker; Franciscus Bernardus Gemma & Van Dalen; Frans & Lemmens; Jacobus Maria & Peters; Theodorus Hendricus Antonium & Picha; Frantisek
    Assignee(s): Synthon B. V.
    The invention relates to a compound, and pharmaceutically acceptable salts, having the formula I: ##STR1## wherein: R represents an alkyl or alkynyl group having 1-4 carbon atoms, or a phenyl group optionally substituted by C.sub.1-4 alkyl, alkylthio, alkoxy, halogen, nitro, acylamino, methylsulfonyl or methylenedioxy, or represents tetrahydronaphthyl, R.sup.1 represents hydrogen, trifluoro (C.sub.1-4) alkyl, alkyl or alkynyl, X represents hydrogen, alkyl having 1-4 carbon atoms, alkoxy, trifluoroalkyl, hydroxy, halogen, methylthio or aralkoxy, R.sup.2 represents: a C1-C10 alkyl group, a phenyl group optionally substituted by one or more of the following groups: a C1-C10 alkyl group, a halogen group, a nitro group, hydroxy group, and/or an alkoxy group.
    Patent expiration dates:

    • June 10, 2017
      ✓ 
      Patent use: OBSESSIVE COMPULSIVE DISORDER


    • June 10, 2017
      ✓ 
      Patent use: TREATMENT OF PANIC DISORDER


    • June 10, 2017
      ✓ 
      Patent use: DEPRESSION




  • N-formyl derivatives of paroxetine
    Patent 6,703,408
    Issued: March 9, 2004
    Inventor(s): Hans J.; Hoorn & Theodorus H. A.; Peters & Frantisek; Picha
    Assignee(s): Synthon BCT Technologies, LLC
    A compound or composition comprising N-formyl paroxetine of formula (1) is useful as a pharmaceutical and as a synthetic intermediate. The N-formyl paroxetine can be an impurity in paroxetine substances and methods of assaying for such an impurity are also useful.
    Patent expiration dates:

    • October 21, 2022
      ✓ 
      Drug product




  • Crystalline paroxetine methane sulfonate
    Patent 7,598,271
    Issued: October 6, 2009
    Inventor(s): Benneker; Franciscus Bernardus Gemma & Van Dalen; Frans & Lemmens; Jacobus Maria & Peters; Theodorus Hendricus Antonium & Picha; Frantisek
    Assignee(s): Noven Therapeutics, LLC
    The invention relates to a compound, and pharmaceutically acceptable salts, having the formula I: wherein: R represents an alkyl or alkynyl group having 1-4 carbon atoms, or a phenyl group optionally substituted by C1-4 alkyl, alkylthio, alkoxy, halogen, nitro, acylamino, methylsulfonyl or methylenedioxy, or represents tetrahydronaphthyl, R1 represents hydrogen, trifluoro (C1-4) alkyl, alkyl or alkynyl, X represents hydrogen, alkyl having 1-4 carbon atoms, alkoxy, trifluoroalkyl, hydroxy, halogen, methylthio or aralkoxy, R2 represents: a C1-C10 alkyl group, a phenyl group optionally substituted by one or more of the following groups: a C1-C10 alkyl group, a halogen group, a nitro group, hydroxy group, and/or an alkoxy group.
    Patent expiration dates:

    • February 11, 2023
      ✓ 
      Drug substance
      ✓ 
      Drug product



See also...

  • Pexeva Consumer Information (Wolters Kluwer)
  • Pexeva Consumer Information (Cerner Multum)
  • Pexeva Advanced Consumer Information (Micromedex)
  • Paroxetine Consumer Information (Drugs.com)
  • Paroxetine Consumer Information (Wolters Kluwer)
  • Paroxetine Controlled-Release Tablets Consumer Information (Wolters Kluwer)
  • Paroxetine Mesylate Consumer Information (Wolters Kluwer)
  • Paroxetine Suspension Consumer Information (Wolters Kluwer)
  • Paroxetine Consumer Information (Cerner Multum)
  • Paroxetine Advanced Consumer Information (Micromedex)
  • Paroxetine Hydrochloride AHFS DI Monographs (ASHP)

Homoclicin




Homoclicin may be available in the countries listed below.


Ingredient matches for Homoclicin



Homochlorcyclizine

Homochlorcyclizine dihydrochloride (a derivative of Homochlorcyclizine) is reported as an ingredient of Homoclicin in the following countries:


  • Japan

International Drug Name Search

Erythromycine




Erythromycine may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Erythromycine



Erythromycin

Erythromycin is reported as an ingredient of Erythromycine in the following countries:


  • Georgia

  • Netherlands

Erythromycin lactobionate (a derivative of Erythromycin) is reported as an ingredient of Erythromycine in the following countries:


  • Netherlands

International Drug Name Search

Precose


Precose is a brand name of acarbose, approved by the FDA in the following formulation(s):


PRECOSE (acarbose - tablet; oral)



  • Manufacturer: BAYER HLTHCARE

    Approval date: September 6, 1995

    Strength(s): 100MG [AB], 50MG [AB]


  • Manufacturer: BAYER HLTHCARE

    Approval date: May 29, 1997

    Strength(s): 25MG [RLD][AB]

Has a generic version of Precose been approved?


Yes. The following products are equivalent to Precose:


acarbose tablet; oral



  • Manufacturer: EMCURE PHARMS LTD

    Approval date: February 7, 2012

    Strength(s): 100MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: IMPAX LABS

    Approval date: May 14, 2009

    Strength(s): 100MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: MYLAN

    Approval date: January 6, 2011

    Strength(s): 100MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: ROXANE

    Approval date: May 7, 2008

    Strength(s): 100MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: STRIDES ARCOLAB LTD

    Approval date: July 27, 2011

    Strength(s): 100MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: WATSON LABS

    Approval date: May 7, 2008

    Strength(s): 100MG [AB], 25MG [AB], 50MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Precose. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Precose.

See also...

  • Precose Consumer Information (Wolters Kluwer)
  • Precose Consumer Information (Cerner Multum)
  • Precose Advanced Consumer Information (Micromedex)
  • Precose AHFS DI Monographs (ASHP)
  • Acarbose Consumer Information (Wolters Kluwer)
  • Acarbose Consumer Information (Cerner Multum)
  • Acarbose Advanced Consumer Information (Micromedex)
  • Acarbose AHFS DI Monographs (ASHP)

Mirapex ER


See also: Generic Mirapex


Mirapex ER is a brand name of pramipexole, approved by the FDA in the following formulation(s):


MIRAPEX ER (pramipexole dihydrochloride - tablet, extended release; oral)



  • Manufacturer: BOEHRINGER INGELHEIM

    Approval date: February 19, 2010

    Strength(s): 0.375MG [RLD], 0.75MG, 1.5MG, 3MG, 4.5MG


  • Manufacturer: BOEHRINGER INGELHEIM

    Approval date: June 17, 2011

    Strength(s): 2.25MG, 3.75MG

Has a generic version of Mirapex ER been approved?


No. There is currently no therapeutically equivalent version of Mirapex ER available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Mirapex ER. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
    Patent 7,695,734
    Issued: April 13, 2010
    Inventor(s): Friedl; Thomas & Eisenreich; Wolfram
    Assignee(s): Boehringer Ingelheim International GmbH
    An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least one water swelling polymer other than pregelatinized starch.
    Patent expiration dates:

    • April 26, 2028
      ✓ 
      Drug product



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • February 19, 2013 - NEW DOSAGE FORM

    • March 19, 2013 - TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE

See also...

  • Mirapex ER Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Mirapex ER Consumer Information (Cerner Multum)
  • Mirapex ER Advanced Consumer Information (Micromedex)
  • Pramipexole Consumer Information (Wolters Kluwer)
  • Pramipexole Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Pramipexole Consumer Information (Cerner Multum)
  • Pramipexole Advanced Consumer Information (Micromedex)
  • Pramipexole Dihydrochloride AHFS DI Monographs (ASHP)

Ebastin Aristo




Ebastin Aristo may be available in the countries listed below.


Ingredient matches for Ebastin Aristo



Ebastine

Ebastine is reported as an ingredient of Ebastin Aristo in the following countries:


  • Germany

International Drug Name Search